Codexis to share RNA manufacturing advances at TIDES USA

Rhea-AI Summary

Codexis (NASDAQ: CDXS) will present RNA manufacturing advances at TIDES USA, May 11–14 in Boston. Presentations cover ECO Synthesis® platform results on phosphorothioate stereochemistry control, ligation efficiency, process performance, and sustainability. Codexis will host a panel and maintain a booth (821) during the conference.

Key Figures

TIDES USA dates: May 11–14 Spotlight time: May 14, 8:30–9:00 a.m. TIDES Talk time: May 13, 10:25–10:35 a.m. +3 more

6 metrics

TIDES USA dates May 11–14 Conference dates at Hynes Convention Center, Boston

Spotlight time May 14, 8:30–9:00 a.m. Controlling phosphorothioate stereochemistry session

TIDES Talk time May 13, 10:25–10:35 a.m. Superior ligation solutions presentation

Conference presentation time May 13, 4:15–4:45 p.m. Advancing sustainability in oligonucleotide manufacturing

Booth number 821 Codexis presence on TIDES USA exhibit floor

Panel date Tuesday, May 12 Expert panel on stereochemistry in RNAi manufacturing

Market Reality Check

Price: $2.81 Vol: Volume 1,301,952 is sligh...

normal vol

$2.81 Last Close

Volume Volume 1,301,952 is slightly below the 20-day average of 1,449,388 (relative volume 0.9x). normal

Technical Shares at $2.815 are trading above the 200-day MA of $2.07 and 27.26% below the 52-week high.

Peers on Argus

CDXS gained 6.42% while close peers were mixed: OABI -4.11%, SLN -0.65%, ACIU +4...

CDXS gained 6.42% while close peers were mixed: OABI -4.11%, SLN -0.65%, ACIU +4.48%, PRQR 0%, VOR +2.93%. Moves do not indicate a unified sector trend.

Historical Context

5 past events · Latest: Apr 23 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Apr 23	Earnings date notice	Neutral	+2.0%	Announcement of Q1 2026 earnings release date and conference call details.
Mar 11	Earnings results	Positive	+34.6%	Q4 and FY 2025 results with ECO Synthesis momentum and 2026 revenue guidance.
Mar 04	Platform agreement	Positive	+10.2%	Agreement to manufacture 50 g siRNA using ECO Synthesis for a preclinical program.
Feb 25	Earnings date notice	Neutral	+1.4%	Scheduling of Q4 and FY 2025 results release and webcast information.
Feb 17	Conference participation	Neutral	+0.8%	Participation in TD Cowen health care conference and planned fireside chat.

Pattern Detected

Recent CDXS news, including earnings and ECO Synthesis updates, has generally coincided with positive next-day price reactions, even for neutral event notices.

Recent Company History

Over the past six months, Codexis has highlighted earnings, ECO Synthesis platform traction and investor events. The Mar 11 FY 2025 earnings release, with ECO Synthesis momentum and Merck technology transfer revenue, saw a 34.65% move. The Mar 4 ECO Synthesis siRNA manufacturing agreement correlated with a 10.2% gain. Conference and earnings-date announcements in February and April also had modest positive reactions, framing today’s TIDES USA technical update within a pattern of constructive responses to visibility and platform news.

Market Pulse Summary

This announcement spotlights Codexis’s ECO Synthesis platform through multiple TIDES USA presentatio...

Analysis

This announcement spotlights Codexis’s ECO Synthesis platform through multiple TIDES USA presentations, emphasizing RNAi manufacturing scalability, phosphorothioate stereochemistry control and ligation efficiency. It continues a series of updates linking ECO Synthesis to siRNA production and industry engagement. Investors evaluating this news may focus on how these technical advances translate into additional contracts, revenue beyond prior ECO Synthesis agreements, and further regulatory engagement milestones, as flagged in earlier FY 2025 and platform-related disclosures.

Key Terms

rna, rnai, oligonucleotide, sirna

4 terms

rna medical

"share RNA manufacturing advances at TIDES USA, held May 11–14"

RNA (ribonucleic acid) is a natural molecule that carries instructions from a cell’s DNA to make proteins and can also act as a tool to turn genes on or off; think of it as a messenger or software that tells biological machinery what to build or modify. It matters to investors because RNA-based tests and therapies can create new markets or change treatment costs and regulatory risk, so progress or setbacks in RNA science often drive valuation swings in biotech companies.

rnai medical

"As RNAi therapies expand into larger indications, manufacturing scalability"

RNAi, short for RNA interference, is a natural cellular process that acts like a mute button for specific genes by using small RNA molecules to stop a target gene from producing its protein. For investors, RNAi matters because it is the underlying mechanism behind a class of precision medicines that can silence disease-causing genes, offering high potential returns but also scientific, regulatory and manufacturing risks unique to novel drug platforms.

oligonucleotide medical

"Challenges and Innovations in Oligonucleotide ManufacturingStefan Lutz, PhD."

A short chain of DNA or RNA molecules used to target, detect, or change specific genetic messages inside cells; think of it as a tiny, programmable instruction or zip code that can find and bind one exact genetic sentence. Investors care because oligonucleotides are the active ingredient in a growing class of precision therapies and diagnostics, so their success, manufacturing cost, and regulatory approval can directly affect a company's value and future revenue.

sirna medical

"sustainability advantages of siRNA manufacturing approaches. Codexis’ technical experts"

Small interfering RNA (siRNA) is a short strand of genetic material that binds to and destroys the messenger RNA that carries instructions for making a specific protein, effectively switching that gene off. Investors care because siRNA is a platform for precise medicines: successful trials or approvals can create high-value drugs, while delivery challenges, manufacturing complexity, patent positions and regulatory risk can sharply affect a biotech company's prospects.

AI-generated analysis. Not financial advice.

REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS) a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, will present new data on ECO Synthesis® Manufacturing Platform and provide an update on regulatory engagement for its enzymatic platform at TIDES USA, held May 11–14 at the Hynes Convention Center in Boston.

As RNAi therapies expand into larger indications, manufacturing scalability, maintaining process control and delivering high-quality product is critical. Codexis will present data demonstrating advances in controlling phosphorothioate stereochemistry, improved ligation efficiency and process performance, alongside the sustainability advantages of siRNA manufacturing approaches.

Codexis’ technical experts will present at three sessions during the conference:

Spotlight Presentation:
Controlling Phosphorothioate Stereochemistry: Challenges and Innovations in Oligonucleotide Manufacturing
Stefan Lutz, PhD., Chief Scientific Officer
Thursday, May 14, 8:30–9:00 a.m.

TIDES Talk:
Superior Ligation Solutions for Scalable RNA Manufacturing
Derek Gauntlett, Vice President, Development
Wednesday, May 13, 10:25–10:35 a.m.

Conference Presentation:
Advancing Sustainability through Innovation in Oligonucleotide Manufacturing
David Entwistle, PhD., Senior Director, Program and Pipeline Management
Wednesday, May 13, 4:15–4:45 p.m.

In addition to Codexis’ talks and booth (821) presence at TIDES USA, Codexis will also host an expert panel discussion and networking event, “Stereochemistry in RNAi Manufacturing: Signal or Noise?”, on Tuesday, May 12. This panel will explore the growing industry focus on stereochemical control, manufacturing options, and its implications for therapeutic performance, and product quality. Panellists include:

• John Maraganore, PhD., Founder and Former CEO at Alnylam
• Fred Fleitz, PhD., SVP of CMC and Development Chemistry at Arrowhead Pharmaceuticals
• Alison Moore, PhD., President and CEO at Codexis
• Raman Sehgal, Entrepreneur, and Host of the Molecule to Market Podcast

About Codexis, Inc.

Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver^® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit codexis.com.

For investor inquiries:
Georgia Erbez
(650) 421-8100
ir@codexis.com

For media inquiries:
aranda@ramarketingpr.com

FAQ

What will Codexis (CDXS) present at TIDES USA May 11–14, 2026?

Codexis will present technical data on its ECO Synthesis® manufacturing platform and process performance improvements. According to Codexis, talks address stereochemistry control, improved ligation efficiency, and sustainability in siRNA and oligonucleotide manufacturing.

When and where are Codexis (CDXS) speaking sessions at TIDES USA 2026?

Codexis speakers appear across May 13–14, 2026 at the Hynes Convention Center in Boston. According to Codexis, sessions include May 13 (10:25 a.m., 4:15 p.m.) and May 14 (8:30 a.m.) with multiple technical presentations.

Who are the Codexis presenters and panelists at TIDES USA 2026?

Presenters include Stefan Lutz, Derek Gauntlett, and David Entwistle; panelists include Alison Moore and industry guests. According to Codexis, John Maraganore and Fred Fleitz are among invited panel participants discussing stereochemistry in RNAi manufacturing.

What topics will Codexis' expert panel discuss on May 12, 2026?

The panel will explore stereochemical control, manufacturing options, and implications for therapeutic performance and product quality. According to Codexis, the discussion aims to evaluate industry trends and technical challenges in RNAi manufacturing.

Where can investors find Codexis at TIDES USA and how can they engage?

Codexis will have a booth at 821 and host a networking panel during the conference. According to Codexis, attendees can visit booth 821, attend presentations, and join the May 12 panel event for technical dialogue.